[{"data":1,"prerenderedAt":191},["ShallowReactive",2],{"drug-cannabidiol":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":35,"contraindications":88,"warnings":98,"renal":106,"monitoring":107,"interactions":108,"review":109,"examples":112,"atc":128,"iran":130,"usApproval":137,"links":143,"populations":157},"cannabidiol",1,{"fa":7,"en":8},"کانابیدیول","Cannabidiol","nervous-system",{"fa":11,"en":12},"کانابینوئید ضدتشنج","Cannabinoid antiseizure drug",[14],{"name":15,"market":16},"Epidiolex","US",[18,19,20,7],"epidiolex","اپیدیولکس","CBD",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":30,"refs":31},"sol-100","solution","oral","100 mg\u002FmL oral solution",{"amount":28,"unit":29,"perVolumeMl":5},100,"mg",[16],[32],{"source":33,"section":34},"fda-epidiolex","3",[36,64,75],{"id":37,"disease":38,"label":39,"population":42,"type":45,"unit":29,"dose":46,"refs":50,"notes":53},"lgs","lennox-gastaut",{"fa":40,"en":41},"لنوکس-گاستو یا دراوه (۱ سال به بالا) — شروع ۲٫۵ mg\u002Fkg دو بار؛ پس از یک هفته ۵ mg\u002Fkg دو بار (تا ۱۰ mg\u002Fkg دو بار)","Lennox-Gastaut or Dravet (≥1 y) — start 2.5 mg\u002Fkg twice daily; after one week 5 mg\u002Fkg twice daily (up to 10 mg\u002Fkg twice daily)",{"minAge":43},{"value":5,"unit":44},"year","weightBased",{"perKgPerDose":47,"perKgPerDoseMax":48,"intervalHours":49},2.5,10,12,[51],{"source":33,"section":52},"2.2",[54],{"text":55,"refs":58},{"fa":56,"en":57},"نگهدارنده توصیه‌شده ۵ mg\u002Fkg دو بار؛ افزایش هفتگی ۲٫۵ mg\u002Fkg دو بار تا ۱۰ mg\u002Fkg دو بار. پیش از شروع ALT، AST و بیلی‌روبین. نارسایی متوسط\u002Fشدید کبد طبق جدول ۱.","Recommended maintenance 5 mg\u002Fkg twice daily; weekly steps of 2.5 mg\u002Fkg twice daily up to 10 mg\u002Fkg twice daily. ALT, AST and bilirubin before starting. Moderate\u002Fsevere hepatic impairment per Table 1.",[59,60,62],{"source":33,"section":52},{"source":33,"section":61},"2.1",{"source":33,"section":63},"2.6",{"id":65,"disease":66,"label":67,"population":70,"type":45,"unit":29,"dose":72,"refs":73},"dravet","dravet-syndrome",{"fa":68,"en":69},"سندرم دراوه (۱ سال به بالا) — شروع ۲٫۵ mg\u002Fkg دو بار؛ نگهدارنده ۵ mg\u002Fkg دو بار (تا ۱۰)","Dravet syndrome (≥1 y) — start 2.5 mg\u002Fkg twice daily; maintenance 5 mg\u002Fkg twice daily (up to 10)",{"minAge":71},{"value":5,"unit":44},{"perKgPerDose":47,"perKgPerDoseMax":48,"intervalHours":49},[74],{"source":33,"section":52},{"id":76,"disease":77,"label":78,"population":81,"type":45,"unit":29,"dose":83,"refs":85},"tsc","tuberous-sclerosis",{"fa":79,"en":80},"تشنج توبروس اسکلروزیس (۱ سال به بالا) — شروع ۲٫۵ mg\u002Fkg دو بار؛ هفتگی تا ۱۲٫۵ mg\u002Fkg دو بار","Tuberous sclerosis seizures (≥1 y) — start 2.5 mg\u002Fkg twice daily; weekly up to 12.5 mg\u002Fkg twice daily",{"minAge":82},{"value":5,"unit":44},{"perKgPerDose":47,"perKgPerDoseMax":84,"intervalHours":49},12.5,[86],{"source":33,"section":87},"2.3",[89],{"id":90,"severity":91,"text":92,"refs":95},"hyper","block",{"fa":93,"en":94},"حساسیت به کانابیدیول یا اجزای فرآورده.","Hypersensitivity to cannabidiol or any ingredient.",[96],{"source":33,"section":97},"4",[99],{"text":100,"refs":103},{"fa":101,"en":102},"آسیب کبدی (به‌ویژه با والپروات) — آنزیم کبد پایش؛ خواب‌آلودگی؛ افکار خودکشی؛ قطع تدریجی.","Hepatocellular injury (especially with valproate) — monitor liver enzymes; somnolence and sedation; suicidal thoughts; withdraw gradually.",[104],{"source":33,"section":105},"5",[],[],[],{"status":110,"reviewer":111,"date":111},"unverified",null,[113,121,124],{"regimen":37,"formulation":23,"input":114,"expect":117},{"ageYears":115,"weightKg":116},6,20,{"perDose":118,"mlPerDose":119,"upperPerDose":120},50,0.5,200,{"regimen":65,"formulation":23,"input":122,"expect":123},{"ageYears":115,"weightKg":116},{"perDose":118,"mlPerDose":119,"upperPerDose":120},{"regimen":76,"formulation":23,"input":125,"expect":126},{"ageYears":115,"weightKg":116},{"perDose":118,"mlPerDose":119,"upperPerDose":127},250,[129],"N03AX24",{"status":131,"refs":132},"not-found",[133],{"source":134,"section":135,"url":136},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Cannabidiol",{"kind":138,"refs":139,"id":142},"NDA",[140],{"source":33,"section":141},"SPL approval \u002F marketing category","NDA210365",[144,147,151,154],{"kind":145,"url":146,"label":142},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=210365",{"kind":148,"url":149,"label":150},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec","FDA Epidiolex",{"kind":152,"url":153,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa618051.html",{"kind":155,"url":156,"label":129},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N03AX24",{"pregnancy":158,"lactation":167,"pediatric":175,"geriatric":183},{"level":159,"text":160,"quote":163,"refs":164},"caution",{"fa":161,"en":162},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","… • North American Antiepileptic Drug (NAAED) Pregnancy Registry o 1-888-233-2334 o https:\u002F\u002Fwww.aedpregnancyregistry.org\u002F Risk Summary There are no adequate data on the developmental risks associated with the use of EPIDIOLEX in pregnant women.",[165],{"source":33,"section":166},"8.1",{"level":159,"text":168,"quote":171,"refs":172},{"fa":169,"en":170},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of cannabidiol or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.",[173],{"source":33,"section":174},"8.2",{"level":159,"text":176,"quote":179,"refs":180},{"fa":177,"en":178},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of EPIDIOLEX for the treatment of seizures associated with LGS, DS, or TSC have been established in patients 1 year of age and older.",[181],{"source":33,"section":182},"8.4",{"level":159,"text":184,"quote":187,"refs":188},{"fa":185,"en":186},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Dosage and Administration ( 2.6 ), Warnings and Precautions …",[189],{"source":33,"section":190},"8.5",1792191530925]